186 related articles for article (PubMed ID: 37204744)
1. Laboratory Testing for von Willebrand Factor Activity by a Glycoprotein Ib-Binding Assay (VWF:GPIbR): HemosIL von Willebrand Factor Ristocetin Cofactor Activity on ACL TOP
Seidizadeh O; Peyvandi F
Methods Mol Biol; 2023; 2663():669-677. PubMed ID: 37204744
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients.
Vangenechten I; Mayger K; Smejkal P; Zapletal O; Michiels JJ; Moore GW; Gadisseur A
J Thromb Haemost; 2018 Jul; 16(7):1268-1277. PubMed ID: 29742318
[TBL] [Abstract][Full Text] [Related]
3. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb).
Patzke J; Favaloro EJ
Methods Mol Biol; 2017; 1646():453-460. PubMed ID: 28804847
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease.
Stufano F; Baronciani L; Bucciarelli P; Boscarino M; Colpani P; Pagliari MT; Peyvandi F
Haemophilia; 2020 Mar; 26(2):298-305. PubMed ID: 32107842
[TBL] [Abstract][Full Text] [Related]
5. Laboratory Testing for von Willebrand Disease Using a Composite Rapid 3-Test Chemiluminescence-Based von Willebrand Factor Assay Panel.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():647-667. PubMed ID: 37204743
[TBL] [Abstract][Full Text] [Related]
6. Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry.
Sagheer S; Rodgers S; Yacoub O; Dauer R; Mcrae S; Duncan E
Haemophilia; 2016 May; 22(3):e200-7. PubMed ID: 27076201
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant differences between assays for von Willebrand factor activity.
Boender J; Eikenboom J; van der Bom JG; Meijer K; de Meris J; Fijnvandraat K; Cnossen MH; Laros-van Gorkom BAP; van Heerde WL; Mauser-Bunschoten EP; de Maat MPM; Leebeek FWG;
J Thromb Haemost; 2018 Dec; 16(12):2413-2424. PubMed ID: 30358069
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
Favaloro EJ
Methods Mol Biol; 2017; 1646():391-402. PubMed ID: 28804843
[TBL] [Abstract][Full Text] [Related]
10. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000).
Lattuada A; Preda L; Sacchi E; Gallo L; Federici AB; Rossi E
Blood Coagul Fibrinolysis; 2004 Sep; 15(6):505-11. PubMed ID: 15311161
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
Favaloro EJ; Mohammed S
Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
[TBL] [Abstract][Full Text] [Related]
12. HemosIL VWF:GPIbR Assay Has a Greater Sensitivity than VWF:RCo Technique to Detect Acquired von Willebrand Syndrome in Myeloproliferative Neoplasms.
Laporte P; Tuffigo M; Ryman A; Fiore M; Rivière E; James C; Guy A
Thromb Haemost; 2022 Oct; 122(10):1673-1682. PubMed ID: 35322397
[TBL] [Abstract][Full Text] [Related]
13. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel flow cytometric immunobead array to quantify VWF: Ag and VWF: GPIbR and its application in acute myocardial infarction.
Yan B; Xu M; Zhao Y; Guo H; Xia L; Ruan C; Zhao Y
Eur J Haematol; 2017 Sep; 99(3):207-215. PubMed ID: 28523822
[TBL] [Abstract][Full Text] [Related]
15. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease.
Verfaillie CJ; De Witte E; Devreese KM
Int J Lab Hematol; 2013 Oct; 35(5):555-65. PubMed ID: 23551532
[TBL] [Abstract][Full Text] [Related]
16. Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers.
Szederjesi A; Baronciani L; Budde U; Castaman G; Colpani P; Lawrie AS; Liu Y; Montgomery R; Peyvandi F; Schneppenheim R; Patzke J; Bodó I
J Thromb Haemost; 2020 Oct; 18(10):2513-2523. PubMed ID: 32573891
[TBL] [Abstract][Full Text] [Related]
17. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays.
Favaloro EJ; Mohammed S
Thromb Res; 2014 Dec; 134(6):1292-300. PubMed ID: 25300811
[TBL] [Abstract][Full Text] [Related]
18. A Comparative Evaluation of an Automated Functional Assay for Von Willebrand Factor Activity in Type 1 Von Willebrand Disease.
Lai SW; Chang CY; Cheng SN; Hu SH; Lai CY; Chen YC
Int J Gen Med; 2021; 14():5167-5174. PubMed ID: 34511999
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies.
Favaloro EJ; Oliver S; Mohammed S; Vong R
Haemophilia; 2020 May; 26(3):503-512. PubMed ID: 32159272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
